VivoSeq
Other

Heart Attack

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Heart Attack is an early-stage landscape with 0 programs across 4 companies. The most active players are Novo Nordisk, Bayer, Viatris Innovation GmbH.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalV

Viatris Innovation GmbH

0 programs

PreclinicalK

KAI Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed14 · 70%
Recruiting4 · 20%
Terminated2 · 10%

Clinical Trials

Trial Activity

20 trials

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT07301034·332 enrolled
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
Recruiting·UUniversity of Sydney·Phase 3·NCT03998319·445 enrolled
Doxycycline to Protect Heart Muscle After Heart Attacks
Recruiting·UUniversity of Alberta·Phase 2·NCT03508232·170 enrolled
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT06118281·10,000 enrolled
Safety Study of AMI MultiStem® to Treat Heart Attacks
Completed·—·Phase 1·NCT00677222·25 enrolled
A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks
Completed·—·Phase 2·NCT00604695·40 enrolled
Which Therapy for Acute Heart Attacks? (The WEST Study)
Completed·UUniversity of Alberta·Phase 2/3·NCT00121446·300 enrolled
Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack
Completed·NNHS Greater Glasgow and Clyde·Phase 4·NCT00132093·100 enrolled
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000542
Beta-Blocker Heart Attack Trial (BHAT)
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000492
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
Completed·Bayer logoBayer·Phase 2·NCT04304534·1,601 enrolled
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
Completed·VViatris Innovation GmbH·Phase 2·NCT03487445·48 enrolled
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00684060·87 enrolled
Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00684021·120 enrolled
Study of Oral PG-116800 Following a Heart Attack
Completed·—·Phase 2·NCT00067236·253 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)